Tags

Type your tag names separated by a space and hit enter

A new look at the second-generation antiepileptic drugs: a decade of experience.
Neurologist 2007; 13(3):133-9N

Abstract

OBJECTIVE

To review data from the literature regarding the efficacy and tolerability of the second-generation antiepileptic drugs which were approved by the Food and Drug Administration (FDA) since 1994.

METHODS

A MEDLINE search of the literature, as well as review of bibliographies, was performed to identify randomized controlled trials and other reports evaluating efficacy, pharmacokinetic profile, adverse effects, and drug interactions of the second-generation antiepileptic drugs. Key search terms included felbamate, gabapentin, lamotrigine, topiramate, tiagabine, levetiracetam, oxcarbazepine, zonisamide, and pregabalin.

RESULTS

Each of the second-generation antiepileptic drugs has demonstrated statistically significant reductions in seizure frequency over baseline compared with placebo or active control. Limited studies of efficacy of the new agents compared with the traditional antiepileptic drugs found no significant differences. Each of the second-generation antiepileptic drugs has a unique pharmacokinetic and side-effect profile. Compared with the traditional agents, the second-generation antiepileptic drugs have fewer serious adverse effects, as well as drug interactions.

CONCLUSION

Knowledge of the second-generation antiepileptic drugs has greatly expanded over the past decade. The newer agents offer many options in the treatment of epilepsy that are safe, efficacious, and well tolerated.

Authors+Show Affiliations

Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA. Suzette.LaRoche@emoryhealthcare.org

Pub Type(s)

Historical Article
Journal Article
Review

Language

eng

PubMed ID

17495757

Citation

LaRoche, Suzette M.. "A New Look at the Second-generation Antiepileptic Drugs: a Decade of Experience." The Neurologist, vol. 13, no. 3, 2007, pp. 133-9.
LaRoche SM. A new look at the second-generation antiepileptic drugs: a decade of experience. Neurologist. 2007;13(3):133-9.
LaRoche, S. M. (2007). A new look at the second-generation antiepileptic drugs: a decade of experience. The Neurologist, 13(3), pp. 133-9.
LaRoche SM. A New Look at the Second-generation Antiepileptic Drugs: a Decade of Experience. Neurologist. 2007;13(3):133-9. PubMed PMID: 17495757.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A new look at the second-generation antiepileptic drugs: a decade of experience. A1 - LaRoche,Suzette M, PY - 2007/5/15/pubmed PY - 2007/7/19/medline PY - 2007/5/15/entrez SP - 133 EP - 9 JF - The neurologist JO - Neurologist VL - 13 IS - 3 N2 - OBJECTIVE: To review data from the literature regarding the efficacy and tolerability of the second-generation antiepileptic drugs which were approved by the Food and Drug Administration (FDA) since 1994. METHODS: A MEDLINE search of the literature, as well as review of bibliographies, was performed to identify randomized controlled trials and other reports evaluating efficacy, pharmacokinetic profile, adverse effects, and drug interactions of the second-generation antiepileptic drugs. Key search terms included felbamate, gabapentin, lamotrigine, topiramate, tiagabine, levetiracetam, oxcarbazepine, zonisamide, and pregabalin. RESULTS: Each of the second-generation antiepileptic drugs has demonstrated statistically significant reductions in seizure frequency over baseline compared with placebo or active control. Limited studies of efficacy of the new agents compared with the traditional antiepileptic drugs found no significant differences. Each of the second-generation antiepileptic drugs has a unique pharmacokinetic and side-effect profile. Compared with the traditional agents, the second-generation antiepileptic drugs have fewer serious adverse effects, as well as drug interactions. CONCLUSION: Knowledge of the second-generation antiepileptic drugs has greatly expanded over the past decade. The newer agents offer many options in the treatment of epilepsy that are safe, efficacious, and well tolerated. SN - 1074-7931 UR - https://www.unboundmedicine.com/medline/citation/17495757/A_new_look_at_the_second_generation_antiepileptic_drugs:_a_decade_of_experience_ L2 - http://dx.doi.org/10.1097/01.nrl.0000256353.14257.7c DB - PRIME DP - Unbound Medicine ER -